7th Eurasian Hematology Oncology Summit
FEATURING Giuseppe Saglio
- 75 views
- December 11, 2020
2020 Efficacy Data on Targeted Therapies in CLL: Do We Need to Combine Rituximab With Ibrutinib for Better PFS? How Does Venetoclax/Obinutuzumab Affect Survival Rates? What’s the Therapeutic Potential of Acalabrutinib?
FEATURING Panayiotis Panayiotidis
- 78 views
- September 28, 2020